Sarepta Therapeutics (NASDAQ:SRPT) Stock Rating Reaffirmed by Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their neutral rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a report published on Friday morning, Benzinga reports. They currently have a $152.00 price target on the biotechnology company’s stock.

SRPT has been the topic of several other reports. Evercore ISI raised shares of Sarepta Therapeutics from an in-line rating to an outperform rating and decreased their price objective for the stock from $185.00 to $179.00 in a research note on Thursday, August 8th. Citigroup lowered their price objective on shares of Sarepta Therapeutics from $176.00 to $160.00 and set a neutral rating for the company in a research report on Thursday, August 8th. Barclays reduced their target price on shares of Sarepta Therapeutics from $226.00 to $203.00 and set an overweight rating on the stock in a research report on Thursday, August 8th. Needham & Company LLC reissued a buy rating and issued a $235.00 price target on shares of Sarepta Therapeutics in a report on Thursday, June 27th. Finally, Bank of America upped their price objective on Sarepta Therapeutics from $166.00 to $213.00 and gave the stock a buy rating in a report on Friday, June 21st. Three research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Sarepta Therapeutics currently has a consensus rating of Moderate Buy and an average target price of $187.39.

Sarepta Therapeutics Trading Up 0.1 %

Shares of Sarepta Therapeutics stock opened at $127.21 on Friday. Sarepta Therapeutics has a 1 year low of $55.25 and a 1 year high of $173.25. The company’s fifty day simple moving average is $137.26 and its 200-day simple moving average is $132.75. The company has a market cap of $12.02 billion, a price-to-earnings ratio of 1,156.45 and a beta of 0.81. The company has a current ratio of 3.90, a quick ratio of 3.19 and a debt-to-equity ratio of 1.05.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.06. Sarepta Therapeutics had a return on equity of 5.32% and a net margin of 3.14%. The business had revenue of $362.90 million for the quarter, compared to the consensus estimate of $394.38 million. During the same period last year, the business earned ($0.27) earnings per share. The firm’s revenue for the quarter was up 38.9% compared to the same quarter last year. As a group, sell-side analysts expect that Sarepta Therapeutics will post 1.47 EPS for the current year.

Insider Buying and Selling

In other Sarepta Therapeutics news, EVP Ryan Edward Brown sold 38,957 shares of the company’s stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $161.61, for a total value of $6,295,840.77. Following the completion of the sale, the executive vice president now owns 17,129 shares of the company’s stock, valued at $2,768,217.69. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, EVP Ryan Edward Brown sold 38,957 shares of the business’s stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $161.61, for a total value of $6,295,840.77. Following the completion of the transaction, the executive vice president now owns 17,129 shares of the company’s stock, valued at approximately $2,768,217.69. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Ian Michael Estepan sold 5,985 shares of the firm’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $137.36, for a total value of $822,099.60. Following the sale, the chief financial officer now directly owns 33,946 shares in the company, valued at approximately $4,662,822.56. The disclosure for this sale can be found here. 7.70% of the stock is owned by insiders.

Institutional Trading of Sarepta Therapeutics

A number of large investors have recently bought and sold shares of SRPT. Innealta Capital LLC bought a new position in Sarepta Therapeutics in the second quarter valued at approximately $31,000. Mather Group LLC. bought a new stake in Sarepta Therapeutics in the 1st quarter valued at $28,000. Riggs Asset Managment Co. Inc. boosted its stake in Sarepta Therapeutics by 125.0% in the 1st quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 125 shares during the period. New Covenant Trust Company N.A. bought a new position in Sarepta Therapeutics during the 1st quarter worth about $32,000. Finally, Principal Securities Inc. acquired a new stake in shares of Sarepta Therapeutics in the 4th quarter valued at about $26,000. 86.68% of the stock is owned by institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.